Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Oxford Immunotec Global Plc's Business Segments
Oxford Immunotec Global Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 19
Regions Reported
2
Oxford Immunotec Global Plc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue Share by Region - FY
- Asia68.4%
- Europe and ROW8.8%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Asia | $ 13 | 68.4% |
| Europe and ROW | $ 2 | 8.8% |
Description of Oxford Immunotec Global Plc
Oxford Immunotec Global Plc is a leading global biotechnology company that specializes in the development, manufacture, and commercialization of innovative tests for immune-related diseases. The company was founded in 2002 and is headquartered in Abingdon, Oxfordshire, United Kingdom.
Oxford Immunotec focuses on advancing the field of T cell immunology and developing tests that harness the power of the immune system to diagnose and monitor diseases such as tuberculosis (TB) and various autoimmune disorders. The company's flagship product is the T-SPOT.TB test, which is a blood-based diagnostic test that accurately detects tuberculosis infection by measuring the activity of T cells in response to specific antigens.
The company's innovative testing platform, T-SPOT technology, enables it to analyze individual T cells and accurately measure their response to disease-specific antigens. This technology provides more accurate and sensitive test results compared to traditional diagnostic methods and has been widely adopted in clinical practice around the world.
Apart from its TB test, Oxford Immunotec also offers a range of diagnostic tests for other immune-related diseases, including tick-borne diseases and autoimmune disorders. These tests utilize the same T-SPOT technology platform, providing clinicians with valuable insights into the immune response and helping to guide treatment decisions.
Oxford Immunotec operates a vertically integrated business model, with in-house capabilities for research and development, manufacturing, and commercialization. The company's state-of-the-art laboratory facilities are equipped with advanced technologies and staffed by a team of experienced scientists and technicians.
In terms of market presence, Oxford Immunotec has successfully expanded its footprint globally. The company has established direct sales operations in key markets such as the United States, Europe, and China, and also partners with local distributors in other regions. This global presence enables Oxford Immunotec to reach healthcare professionals and patients worldwide and provide them with access to its high-quality diagnostic tests.
In addition to its core diagnostic business, Oxford Immunotec also actively participates in collaborative research and development projects. The company collaborates with academic institutions, government agencies, and other industry partners to advance its understanding of T cell immunology and develop new diagnostic and therapeutic solutions.
Overall, Oxford Immunotec Global Plc is a pioneering biotechnology company at the forefront of T cell immunology. With its innovative diagnostic tests and strong global presence, the company is committed to improving patient outcomes and public health by enabling accurate and timely diagnosis of immune-related diseases.
Oxford Immunotec focuses on advancing the field of T cell immunology and developing tests that harness the power of the immune system to diagnose and monitor diseases such as tuberculosis (TB) and various autoimmune disorders. The company's flagship product is the T-SPOT.TB test, which is a blood-based diagnostic test that accurately detects tuberculosis infection by measuring the activity of T cells in response to specific antigens.
The company's innovative testing platform, T-SPOT technology, enables it to analyze individual T cells and accurately measure their response to disease-specific antigens. This technology provides more accurate and sensitive test results compared to traditional diagnostic methods and has been widely adopted in clinical practice around the world.
Apart from its TB test, Oxford Immunotec also offers a range of diagnostic tests for other immune-related diseases, including tick-borne diseases and autoimmune disorders. These tests utilize the same T-SPOT technology platform, providing clinicians with valuable insights into the immune response and helping to guide treatment decisions.
Oxford Immunotec operates a vertically integrated business model, with in-house capabilities for research and development, manufacturing, and commercialization. The company's state-of-the-art laboratory facilities are equipped with advanced technologies and staffed by a team of experienced scientists and technicians.
In terms of market presence, Oxford Immunotec has successfully expanded its footprint globally. The company has established direct sales operations in key markets such as the United States, Europe, and China, and also partners with local distributors in other regions. This global presence enables Oxford Immunotec to reach healthcare professionals and patients worldwide and provide them with access to its high-quality diagnostic tests.
In addition to its core diagnostic business, Oxford Immunotec also actively participates in collaborative research and development projects. The company collaborates with academic institutions, government agencies, and other industry partners to advance its understanding of T cell immunology and develop new diagnostic and therapeutic solutions.
Overall, Oxford Immunotec Global Plc is a pioneering biotechnology company at the forefront of T cell immunology. With its innovative diagnostic tests and strong global presence, the company is committed to improving patient outcomes and public health by enabling accurate and timely diagnosis of immune-related diseases.
Oxford Immunotec Global plc is a biotechnology company that specializes in the development and commercialization of innovative diagnostic tests and services primarily focused on immune response and infectious disease detection. The company is particularly recognized for its expertise in the field of immunology and its commitment to improving patient care through advanced technology.
Major Segments
1. Infectious Disease Testing
- Tuberculosis (TB) Testing: Oxford Immunotec is widely known for its T-SPOT®.TB test, an ELISPOT-based assay designed to detect latent tuberculosis infection (LTBI) by measuring the immune response to specific TB antigens. This test is particularly valuable in populations at risk of TB, such as healthcare workers, immigrants from high-prevalence regions, and immunocompromised individuals.
- Other Infectious Diseases: In addition to TB, the company is expanding its portfolio to include assays for other infectious diseases, such as Lyme disease and COVID-19. These tests often leverage proprietary technologies that assess the immune response rather than relying solely on the presence of pathogens.
2. Autoimmune Disease Testing
- Immunology Assays: Oxford Immunotec offers products that help in understanding various autoimmune conditions by measuring specific immune responses. These assays play a critical role in diagnosing and managing diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis.
3. Transplant Diagnostics
- T Cell-Dependent Immune Response Testing: The company is also involved in the transplant diagnostics space, providing assays that assess immune responses in patients undergoing organ transplantation. This area is crucial for monitoring graft rejection and ensuring patient safety.
4. Research and Development Services
- Oxford Immunotec collaborates with research institutions and pharmaceutical companies to develop custom assays and solutions that facilitate immunological research. These may include targeted immune profiling and support for clinical trials to evaluate new therapeutics.
Products
1. T-SPOT.TB
- An FDA-approved test designed to identify individuals with latent TB infection. The test measures the immune response to specific TB antigens and provides results within 24 hours.
2. QuantiFERON® Tests
- Although primarily part of a different release by QIAGEN, Oxford Immunotec has been involved in developing tests that can measure immune responses using similar strategies.
3. Research and Development Assays
- The companys portfolio includes a range of research assays tailored for clinical laboratories and pharmaceutical companies to assist in studies related to infectious diseases and immune responses.
Services
1. Laboratory Services
- Oxford Immunotec operates various laboratories that provide diagnostic testing services. These labs are equipped with advanced technology to deliver precise and reliable results in a timely manner.
2. Technical Support and Consultation
- The company offers comprehensive technical support and consultancy services to clients, ensuring they have the resources needed to understand and utilize the diagnostic tests effectively.
3. Education and Training
- Providing training programs and educational resources for healthcare professionals to enhance understanding of immunology and the interpretation of assay results forms a vital part of the companys service offerings.
4. Custom Assay Development
- Oxford Immunotec provides bespoke assay development services targeted at fulfilling specific research needs or addressing emerging diagnostic challenges in infectious diseases and immune response profiling.
Summary
Overall, Oxford Immunotecs integrated approach of offering diagnostic tests, laboratory services, and custom research solutions reflects its commitment to advancing immunology and infectious disease detection. The companys products and services are designed to enhance patient outcomes, support healthcare providers, and facilitate critical research in the field of immunology.
Major Segments
1. Infectious Disease Testing
- Tuberculosis (TB) Testing: Oxford Immunotec is widely known for its T-SPOT®.TB test, an ELISPOT-based assay designed to detect latent tuberculosis infection (LTBI) by measuring the immune response to specific TB antigens. This test is particularly valuable in populations at risk of TB, such as healthcare workers, immigrants from high-prevalence regions, and immunocompromised individuals.
- Other Infectious Diseases: In addition to TB, the company is expanding its portfolio to include assays for other infectious diseases, such as Lyme disease and COVID-19. These tests often leverage proprietary technologies that assess the immune response rather than relying solely on the presence of pathogens.
2. Autoimmune Disease Testing
- Immunology Assays: Oxford Immunotec offers products that help in understanding various autoimmune conditions by measuring specific immune responses. These assays play a critical role in diagnosing and managing diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis.
3. Transplant Diagnostics
- T Cell-Dependent Immune Response Testing: The company is also involved in the transplant diagnostics space, providing assays that assess immune responses in patients undergoing organ transplantation. This area is crucial for monitoring graft rejection and ensuring patient safety.
4. Research and Development Services
- Oxford Immunotec collaborates with research institutions and pharmaceutical companies to develop custom assays and solutions that facilitate immunological research. These may include targeted immune profiling and support for clinical trials to evaluate new therapeutics.
Products
1. T-SPOT.TB
- An FDA-approved test designed to identify individuals with latent TB infection. The test measures the immune response to specific TB antigens and provides results within 24 hours.
2. QuantiFERON® Tests
- Although primarily part of a different release by QIAGEN, Oxford Immunotec has been involved in developing tests that can measure immune responses using similar strategies.
3. Research and Development Assays
- The companys portfolio includes a range of research assays tailored for clinical laboratories and pharmaceutical companies to assist in studies related to infectious diseases and immune responses.
Services
1. Laboratory Services
- Oxford Immunotec operates various laboratories that provide diagnostic testing services. These labs are equipped with advanced technology to deliver precise and reliable results in a timely manner.
2. Technical Support and Consultation
- The company offers comprehensive technical support and consultancy services to clients, ensuring they have the resources needed to understand and utilize the diagnostic tests effectively.
3. Education and Training
- Providing training programs and educational resources for healthcare professionals to enhance understanding of immunology and the interpretation of assay results forms a vital part of the companys service offerings.
4. Custom Assay Development
- Oxford Immunotec provides bespoke assay development services targeted at fulfilling specific research needs or addressing emerging diagnostic challenges in infectious diseases and immune response profiling.
Summary
Overall, Oxford Immunotecs integrated approach of offering diagnostic tests, laboratory services, and custom research solutions reflects its commitment to advancing immunology and infectious disease detection. The companys products and services are designed to enhance patient outcomes, support healthcare providers, and facilitate critical research in the field of immunology.